Stocks Under Scanner in the Biotech Space -- Sangamo Therapeutics, Vertex Pharma, Athersys, and AVEO Pharma

Friday, November 10, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 10, 2017 /PRNewswire/ -- If you want a Stock Review on SGMO, VRTX, ATHX, or AVEO then come over to

and sign up for your free customized report. On Thursday, November 09, 2017, the NASDAQ Composite ended the trading session at 6,750.05, down 0.58%; the Dow Jones Industrial Average edged 0.43% lower, to finish at 23,461.94;
and the S&P 500 closed at 2,584.62, slightly dropping 0.38%. Losses were broad based as all sectors ended the day in negative. This Friday, has initiated reports coverage on the following Biotechnology equities: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Athersys Inc. (NASDAQ: ATHX), and AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). Take a look at the free research reports issued today on for these stocks by signing up at:

Sangamo Therapeutics

Richmond, California headquartered Sangamo Therapeutics Inc.'s stock finished Thursday's session 2.93% higher at $12.30 with a total trading volume of 1.45 million shares. The Company's shares have advanced 20.00% in the previous three months, 211.39% over the past twelve months, and 303.28% since the start of this year. The stock is trading above its 200-day moving average by 46.21%. Additionally, shares of Sangamo Therapeutics, which focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy, have a Relative Strength Index (RSI) of 42.22. Sign up and read the free research report on SGMO at:

Vertex Pharmaceuticals

On Thursday, shares in Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc. recorded a trading volume of 1.10 million shares. The stock ended the session 0.52% higher at $148.17. The Company's shares have advanced 59.53% over the last twelve months and 101.13% on an YTD basis. The stock is trading above its 200-day moving average by 16.40%. Moreover, shares of Vertex Pharma, which discovers, develops, manufactures, and commercializes medicines for serious diseases, have an RSI of 45.59.

On October 18th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $175 a share to $181 a share. The complimentary research report on VRTX can be downloaded at:


Cleveland, Ohio headquartered Athersys Inc.'s shares closed the day 3.33% higher at $1.86. The stock recorded a trading volume of 1.10 million shares. The Company's shares have gained 19.23% over the previous three months, 12.05% over the last twelve months, and 21.57% since the start of the year. The stock is trading above its 200-day moving average by 16.34%. Additionally, shares of Athersys, which focuses on the R&D activities in the field of regenerative medicine, have an RSI of 44.95. Register for free on and access the latest report on ATHX at:

AVEO Pharmaceuticals

Shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. finished 2.46% higher at $2.92. The stock recorded a trading volume of 1.46 million shares. The Company's shares have advanced 380.42% over the last twelve months and 440.74% on an YTD basis. The stock is trading above its 200-day moving average by 57.39%. Furthermore, shares of AVEO Pharma, which develops targeted therapies for cancer and related diseases, have an RSI of 41.89. Get free access to your research report on AVEO at:


Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACTFor any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email:  Phone number:  (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store